In recent years, the effect of immune checkpoint inhibitors on the treatment of Hodgkin's lymphoma (HL) is impressive, but the disease still needs to be overcome more thoroughly. Mayo Clinic ’s Lymphoma Group Chairman Ansell sai..
Researchers at the University of California, San Francisco and St. Jude Children ’s Research Hospital in Tennessee have solved medical mysteries decades ago, and they have discovered a pair of genetic mutations that may cause fa..
The FDA has granted its breakthrough drug quizartinib a breakthrough treatment. Quizartinib is a FLT3 inhibitor under investigation for the treatment of adult patients with relapsed / refractory FLT3-ITD acute myeloi..
The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic leukemia (CLL) based on the minimal residual disease (MRD) data of the phase..
According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin's lymphoma.The therapy com..
According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor nivolumab ( nivolumab ) showed that the response rate and recurrence..
On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. It is widely used..
The US FDA has approved gilteritinib ( Xospata ) for the treatment of adult patients with FLT3 mutation-positive relapse or refractory acute myeloid leukemia ( AML ). When used with gil..
The results of a multi-center phase III clinical trial showed that if elderly patients with chronic lymphocytic leukemia ( CLL ) are treated with a new targeted drug ibrutinib compared with the previously commo..
Venetoclax (Venclexta) and rituximab (Rituxan) are used in combination with relapsed / refractory chronic lymphocytic leukemia ( CLL ), resulting in a high rate of undetectable minimal residual disease ( uMRD ), which is as..